vidofludimus zinc

Vidofludimus zinc is a hypothetical zinc salt of the small‑molecule immunomodulator vidofludimus, an orally active dihydroorotate dehydrogenase (DHODH) inhibitor and nuclear receptor-related 1 (Nurr1) activator that has been clinically developed as vidofludimus calcium for multiple sclerosis, ulcerative colitis, and other immune-mediated and viral diseases. By selectively inhibiting mitochondrial DHODH, vidofludimus depletes de novo pyrimidine synthesis in activated lymphocytes, inducing metabolic stress and apoptosis in pathogenic T and B cells while sparing resting lymphocytes, thereby exerting anti-inflammatory effects. Concurrent agonism of Nurr1, a neuroprotective transcription factor, reduces production of pro-inflammatory cytokines and neurotoxic mediators by microglia and astrocytes and supports neuronal survival, providing a dual neuroprotective and anti-inflammatory mechanism relevant to neurodegenerative and demyelinating conditions.[1][3][5][7][9]